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ABSTRACT: The Ah receptor (AHR) has been studied for almost five decades. Yet, we still have
many important questions about its role in normal physiology and development. Moreover, we still
do not fully understand how this protein mediates the adverse effects of a variety of environmental
pollutants, such as the polycyclic aromatic hydrocarbons (PAHs), the chlorinated dibenzo-p-dioxins
(“dioxins”), and many polyhalogenated biphenyls. To provide a platform for future research, we provide the historical underpinnings
of our current state of knowledge about AHR signal transduction, identify a few areas of needed research, and then develop concepts
such as adaptive metabolism, ligand structural diversity, and the importance of proligands in receptor activation. We finish with a
discussion of the cognate physiological role of the AHR, our perspective on why this receptor is so highly conserved, and how we
might think about its cognate ligands in the future.
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■ INTRODUCTION
The role of the Ah receptor (AHR) in human health and
environmental toxicology continues to be an area of
considerable interest. In this review, we provide a brief history
of AHR research, our interpretation of recent discoveries, and
our vision for the research path forward. Owing to the
thousands of publications on this topic, we have attempted to
provide our own perspective on the history of AHR discovery,
current state of knowledge, and opportunities for further
inquiry, rather than perform a comprehensive review. This
approach was taken in an effort to provide a foundation for
future research and present ideas designed to stimulate new
Received: November 29, 2019
Published: April 7, 2020
Perspectivepubs.acs.org/crt
© 2020 American Chemical Society
860
https://dx.doi.org/10.1021/acs.chemrestox.9b00476
Chem. Res. Toxicol. 2020, 33, 860−879
This is an open access article published under an ACS AuthorChoice License, which permits
copying and redistribution of the article or any adaptations for non-commercial purposes.
D
ow
nl
oa
de
d 
vi
a 
M
BL
W
H
O
I L
IB
RA
RY
 o
n 
A
pr
il 
21
, 2
02
0 
at
 1
6:
16
:0
7 
(U
TC
).
Se
e 
ht
tp
s:/
/p
ub
s.a
cs
.o
rg
/sh
ar
in
gg
ui
de
lin
es
 fo
r o
pt
io
ns
 o
n 
ho
w
 to
 le
gi
tim
at
el
y 
sh
ar
e 
pu
bl
ish
ed
 a
rti
cl
es
.
scientific directions. In an effort toward clarity, we try to
emphasize reviews and examples and have not attempted to
generate an exhaustive review of the primary literature. Our
rationale was that these citations will represent the complicated
literature, alternative interpretations of the relevant science,
and can serve as primary citations when further reading is of
interest.
■ THE AH RECEPTOR
Historical Foundations. Polycyclic Aromatic Hydro-
carbons and Discovery of the Ah Locus. Early indications
for the existence of the AHR arose from studies designed to
understand the metabolism of carcinogenic polycyclic aromatic
hydrocarbons (PAHs), such as benzo[a]pyrene (BAP), 7,12-
dimethylbenzanthracene (DMBA), and 3-methylcholanthrene
(3MC) (Figure 1).1,2 Compounds like these arise from
combustion processes and are common contaminants in
chimney soot, charbroiled foods, diesel exhaust, outdoor
burns, cigarette smoke, and coal tar.3−8
In early carcinogen metabolism studies, the prominent
enzymatic activity that oxidized PAHs to hydroxylated
metabolites became known as “aryl hydrocarbon hydroxylase”
or simply “AHH.” From this work, three important
observations arose.9,10 First, AHH activity was the product of
multiple cytochrome P450-dependent monooxygenases
(P450s).11 Second, AHH activity was significantly upregulated,
or “induced”, by prior exposure to a broad spectrum of these
same PAHs.12 Third, in mice, a single autosomal locus harbors
significant control over induction sensitivity across inbred
strains (i.e., some strains were more inducible than others).13
The locus became commonly known as Ah for its role in
regulating AHH activity and was formally renamed the “aryl
hydrocarbon receptor” or Ahr locus in later years.14,15 In
addition to its importance as an early example of carcinogen
metabolism regulation, the AHH system also became a widely
studied model of mammalian enzyme induction and adaptive
metabolism (i.e., exposure to a xenobiotic substrate inducing
its metabolism).16,17
Dibenzo-p-dioxins and Discovery of the Ah Receptor
(AHR). Additional evidence for the existence of an AHR arose
from experiments designed to understand the mechanism of
action of chlorinated dibenzo-p-dioxins and related environ-
mental pollutants.18 Chlorinated dioxins and the related
chlorinated dibenzofurans have never seen commercial use
but are commonly introduced into the environment as trace
contaminants of many industrial processes, anthropogenic
sources, and some natural processes (Figure 2 and Table 1).
The structurally related coplanar polychlorinated biphenyls
(PCBs) and coplanar polybrominated biphenyls (PBBs) have
seen commercial production and are often introduced into the
environment as the result of industrial accident or improper
disposal. As a class, these compounds display similar
environmental fates, are environmentally persistent, are
lipophilic, bioaccumulate in the food chain, and they elicit
similar biological responses dependent upon chlorination
pattern.19−21
The dioxin, 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), is
widely considered as the prototype for this class of environ-
mental pollutant. Exposure to TCDD can lead to a broad
spectrum of species-specific toxic effects, often referred to as
the “dioxin toxic syndrome.” This syndrome commonly
includes epithelial hyperplasia/metaplasia, chloracne, porphy-
ria, late-stage terata, lymphoid involution, intestinal damage,
hepatocellular damage, and cancer.18,22 Dioxins like TCDD are
remarkably potent toxicants, with a median lethal dose (LD50)
that can be in the low μg/kg range in some animal models.23,24
While dioxin toxicology has its research origins from an
agricultural accident in poultry in the late 1950s,25 subsequent
human exposures resulting from numerous pollution sources
and environmental accidents, as well as its presence in the
Vietnam War defoliant known as “Agent Orange”, sparked a
modern effort to understand its mechanism of toxic action
(Table 1).26,27,2829 Despite the popular, regulatory, and
scientific concern that has been in place for decades,
halogenated dioxins, dibenzofurans, and biphenyls can still be
found in human blood samples and in ecosystems around the
globe.19,30−33
It was through investigations into the toxic action of TCDD
that we learned that the Ahr locus encodes a receptor. This
conclusion arose from four observations.18,34−36 First, TCDD
induced the same P450s and related enzymes as did BAP,
DMBA, and 3MC but with much greater potency.37 Second,
radiolabeled dioxin analogues bound to a high affinity, low-
capacity soluble protein site, designated as a receptor in target
tissues.35 Third, binding affinity for this “receptor” site
segregated with the high and low responsiveness (inducibility)
phenotype observed across the C57BL/6 (“responsive”) and
DBA/2 (“nonresponsive”) mouse strains.35,38 Fourth, the rank
order potency for a given ligand’s potency to induce AHH
activity (or many aspects of toxicity) corresponds to its rank
order potency for receptor binding affinity. In sum, the early
Figure 1. Investigations of carcinogenic PAHs led to discovery of the
Ah locus. Studies using BAP, DMBA, and 3-MC provided early
evidence for the existence of the AHR (see text for references).
Figure 2. Further elucidation of the Ah locus arose from toxicity studies using the toxicant TCDD. TCDD, 2,3,7,8-TCDF
(tetrachlorodibenzofuran), and PCB 77 (polychlorinated biphenyl) induce the same P450s and related enzymes as did BAP, DMBA, and 3-
MC. TCDD has higher affinity for AHR and thus has greater potency, making TCDD a model inducer of AHR signaling (see text for details).
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investigations into the genetics of PAH metabolism and the
mechanism of dioxin’s toxic mechanism converged to reveal a
soluble receptor known as the AHR, encoded by the Ahr locus,
and proved that this receptor mediates many of the biological
effects of these environmentally important pollutants.
Biochemical and Molecular Characterization of the
Ah Receptor (AHR). Early Molecular and Biochemical
Insights. A better understanding of AHR signal transduction
arose from a long history of pharmacologic and molecular
studies of the regulatory elements of the genes encoding the
induced enzymes that comprised AHH activity.34,39−41
Although a bit more complex, we now know that AHH and
PAH metabolism can be considered the composite activity of
multiple genetic loci, including, Cyp1a1, Cyp1a2, and Cyp1b1.
Each of the Cyp1 gene products encodes a member of the
cytochrome P450-dependent monooxygenase family with
metabolic activity toward PAH substrates.9,11,42−45
The genomic elements controlling the ligand-activated
AHR-dependent induction were given multiple names over
the years, including xenobiotic responsive elements (XREs),
dioxin responsive elements (DREs), and AHR responsive
elements (AHREs, which we will use here).41,42,46 The
discovery and characterization of these genomic enhancers
were initially based mostly on studies of Cyp1a1 regulation. Of
particular importance were the observations that the enhancers
controlling AHR-mediated upregulation of Cyp1 genes
commonly harbored consensus sequences of 5′-T/
GNGCGTGA/C-3′. For Cyp1a1 and many other inducible
genes, these elements often existed in multiple copies proximal
and 5′ to the transcriptional start site of the target
promoter.44,47−49
Ah Receptor Nuclear Translocator. A significant step in
developing a basic model of AHR signal transduction came
from the molecular cloning of the AHR and its dimerization
partner, the Ah Receptor Nuclear Translocator (ARNT).50−52
These cloning experiments revealed that both the AHR and
ARNT were structurally related, heterodimeric partners,
harboring both basic helix−loop−helix (bHLH) and PER-
Table 1. Well-Known Accidents/Exposures to Dioxin and Dioxin-Like Compounds
location contamination source route of exposure human health implications
example
reference
Belgium transformer oil in fat of animal
feed
poultry, pork, beef,
milk, eggs, and vari-
ous fat-containing
food items
50 kg of PCBs and 1 g of “dioxin” were contaminated in 500 tons of animal feed
and distributed to farms in Belgium and on some nearby countries. 20−30% of
these contaminants were estimated to have been consumed by the Belgian
population.
[271]
Ireland fuel from drying system used
during animal feed production
cattle, pork meat, and
pork products
Significant health concerns by public. Well-documented case of source and movement
of dioxin and related compounds through commerce.
[272,
273]
Seveso, Italy chemical factory accident: un-
controlled exothermic reaction
during the manufacturing of
trichlorophenol
air and soil Immediate effects from cloud deposition: nausea, headache, skin lesions, and eye
irritation. Long-term effects: Chloracne, increased incidence of diabetes, cancer, and
mortality from cardiovascular and respiratory disease.
[274,
275]
Vietnam,
Laos, and
Cambodia
Agent Orange, Agent Pink, Agent
Green, Agent Purple, Agent
White, and Agent Blue: crude
phenoxyacetic acid herbicides
air, soil, surrounding
waters, and ingestion
(legacy through
hand-to-mouth con-
tact)
Found association between dioxin exposure and soft tissue sarcoma, non-Hodgkin’s
Lymphoma, chronic lymphocytic leukemia, Hodgkin’s lymphoma, chloracne,
hypertension, and monoclonal gammopathy. Movement of dioxins into the human
food chain and human tissues and biological fluids decades after use.
[276,
277]
Times
Beach,
Missouri
waste oil used for dust control air and soil Greater than 100 ppb in community. Human, wildlife, and livestock toxicity reported. [278,
279]
Figure 3.Mapping of AHR and ARNT functional domains and founding bHLH-PAS family members. The bHLH domain and N-terminus provide
recognition of target DNA enhancers. The PAS domains control dimerization strength and selectivity, receptor repression, chaperone interactions,
and ligand binding. Approximation of those domains for AHR are depicted as lines above. The C-terminus provides possible docking sites for
coactivators.53−60,63,64,66−69,71,73,74,76,78,79,90,130,280−282 Also see text for further details.
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ARNT-SIM (PAS) homology domains within their N-terminal
halves53,54 (Figure 3). The bHLH domain occurs in metazoan
transcriptional regulators and commonly provides both a
dimerization surface and an α-helix that interacts with specific
sequences in the major and minor grooves of DNA.53,55−59
The PAS homology domain was named based on the similarity
between amino acid sequences within ARNT and the products
of two regulatory loci found in Drosophila melanogaster, PER
and SIM (products of the per and sim loci, respectively).53 In
addition to these two fruit fly gene products, PAS domains
occur in a number of important mammalian regulatory
proteins, including the “hypoxia-inducible factors” (HIFs)
important in physiological adaptation to low oxygen and
“clock” proteins central to the maintenance of circadian
rhythms.60 Importantly, PAS domains have evolutionary roots
in prokaryotic and plant systems, where parallel domains also
play a role in environmental adaptation to stimuli such as light
and oxygen61
Functional Domain Maps. The importance of the bHLH-
PAS region in dimerization and DNA binding is provided by
numerous functional mapping studies in both the AHR and
ARNT.59,62−64 Like many bHLH proteins, the AHR and
ARNT employ this domain as a dimerization surface and use
the basic N-terminal helix to provide recognition of target
DNA enhancers, with each basic region laying within a “half-
site” of the AHRE (e.g., TNGC or GTG).56−58,60,65−67 The
functional role of the PAS domain can be thought of in the
context of its two degenerate repeats or subdomains, referred
to as PAS-A and PAS-B. The PAS-A domain plays a significant
role in supporting the dimerization that drives DNA binding
selectivity. In contrast, the PAS-B domain is important in
dimerization but also harbors domains for receptor stabiliza-
tion, receptor repression, chaperone interactions, and ligand
binding.60,62,68−72
Although the C-terminal halves of the AHR and ARNT are
highly divergent at the sequence level, this region appears to
harbor domains of similar function in the two proteins. Studies
employing fusions of this region with heterologous DNA
binding domains reveal that potent transcriptional activation
domains (TADs) reside within the C-terminal halves of these
proteins, overlapping with glutamine-rich or highly acidic and
disordered regions.73−77 In more recent years, additional
docking domains for some coactivators map to the bHLH-PAS
domains of both the AHR and ARNT78 (Table 2). While our
understanding of coactivator associations is still nascent, the
AHR−ARNT-dimer-mediated transcription of target genes
such as Cyp1a1 appears to involve, at least in part, classical
chromatin modifications and recruitment of members of the
transcription initiation complex.78,79
Adaptive Metabolism Pathway. Model for Adaptive
Metabolism. As the result of the first 50 years of investigation
into the AHR, we have a working model of the functional
domains and signaling steps that regulate the expression of the
xenobiotic-metabolizing enzymes such as CYP1A1 (Figure
4).12,36,46,47,57,72,80 Through the use of molecular reagents from
cloned AHR and ARNT, mutant hepatoma cell lines,
immunochemical tools for localization and precipitation, and
high-affinity radioligands, the importance of subcellular
localization, chaperones, and the ordering of signaling steps
for upregulation of genes is becoming clearer.34,36 The most
common description of AHR signaling as it relates to CYP1A1
gene induction is as follows: In the absence of an inducing
ligand, the AHR protein resides predominantly in the cell’s
cytoplasm in a complex with a number of chaperones,
including a dimer of the 90 kDa heat shock protein (Hsp90)
and smaller chaperones known as the AHR interacting protein
(AIP, also known as ARA9 or XAP2) and the P23
protein.81−88 Upon the binding of ligand to the AHR, a
conformational change in the receptor leads to a reorganization
of chaperones and allows presentation of the NLS in the
AHR’s N-terminus. Translocation of the AHR to the nuclear
compartment then allows dimerization with its nuclear partner,
ARNT.57,83,86 The AHR−ARNT dimer produces a competent
DNA binding dimer with specificity for AHREs within
chromatin and activation of nearby target promoters such as
that for Cyp1a1. While much is still to be learned about this
final transcriptional step, the AHR−ARNT dimer has been
shown to increase promoter accessibility and alter chromatin
structure through association with numerous known coac-
tivators89−97 (see examples in Table 2).
Pathway Feedback Inhibition. One intriguing observation
about AHR signal transduction is that several mechanisms exist
to downregulate this signaling. Primary evidence for the
Table 2. Examples of Some Coactivators That Have Been
Shown to Associate with AHR or Its Complexa
coactivator reference notes
BRCA-1 [283, 284] interaction with both AHR and ARNT
BRG-1 [285, 286] interaction with AHR, enhances
complex activity
CARM-1 [287] interaction with AHR
CoCoA [288] interaction with both AHR and ARNT
COUP-TF1 [289] interaction with AHR and not ARNT
ERα [289] interaction with AHR and not ARNT
ERRα [289] interaction with AHR and not ARNT
ERAP140 [290] interaction with AHR−ARNT complex
GAC63 (GRIP1) [291] interaction with AHR
Mediator [96] interaction with AHR−ARNT complex
P160 (NcoA-1-3) [116] interaction with both AHR and ARNT
NcoA-4 [92] interaction with both AHR and ARNT
P300 [116, 292,
293]
interaction with both AHR and ARNT
PGC-1 [287] interaction with AHR
RB [294] interaction with AHR
RIP140 [295, 296] interaction with AHR, cross talk with
ERα
SHP [297] interaction with ARNT and not AHR
SMRT [290, 298] interaction with AHR−ARNT complex
and AHR
SRC1 (NcoA-1) [282, 287] interaction with AHR Q-rich region
SRC2 (NcoA-2) [287] interaction with AHR
SRC3 (NcoA-3) [287] interaction with AHR
TAF4 [282] interaction with AHR Q-rich region
TAF6 [282] interaction with AHR Q-rich region
TBP [282] interaction with AHR Q-rich region
TIF2 [282] interaction with AHR Q-rich region
TRAP220 [287] interaction with AHR
TRIP230 [299] interaction with ARNT
SIN3A [300] enhances complex activity
aThis table of examples was generated by a cross reference of the
topics, “Ah receptor” and “Coactivator” in the “Web of Science”
search engine of scientific publications, apps.webofknowledge.com
(8/1/2019). It was then supplemented with information found in two
reports on the topic.78,116 Clear, alternative names of coactivators are
given in parentheses. The table is meant to represent the diversity of
known AHR−coactivator interactions and is not intended to be an
exhaustive list.
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importance of feedback inhibition comes from one of the more
recently discovered targets of the ligand-activated AHR−
ARNT complex, an additional bHLH-PAS protein known as
the Ah receptor repressor (AHRR).98,99 The AHRR not only
dimerizes with ARNT and competes for AHRE occupancy but
also inhibits AHRE-mediated transcription by influencing the
chromatin structure around the promoters of CYP1A1 and
presumably related AHRE-driven genes.100,101 In addition to
this upregulated repressor activity, the AHR also appears to be
the target of multiple additional downregulators.102 Not only
has the ligand-activated AHR been shown to be constitutively
degraded by ubiquitination and proteasomal degrada-
tion,103−105 one of its AHRE-driven target genes, Tiparp,
may ADP-ribosylate the AHR, reducing its activity and half-
life.106,107
The existence of AHRE regulated genes such as AHRR and
TIPARP provides support for an additional perspective on
AHR signaling. While we classically think of this system as a
pathway to adapt to PAH molecules generated exogenously or
endogenously, it is also interesting to think of the CYP1A1/
CYP1A2/CYP1B1 gene targets as additional participants in a
negative feedback loop. That is, activation of the AHR by
PAHs (and other ligands described below) leads to the
upregulation of CYP1 monooxygenases and their consequent
metabolic degradation and excretion of inducing ligands. This
would appear to represent a classic substrate inducing its own
metabolism in a feedback loop.12,46,47 These observations lead
to the question: why is so much biology directed toward AHR
downregulation and attenuation of signaling? Possible answers
are that the AHR is part of a biological response that must be
rapidly attenuated to avoid pathological consequences or that
it is part of a chronic response that must be precisely
modulated over time (see below).
More to Be Learned about Functional Domains and
Signaling. It is important to note that this current description
of the AHR domain map and signal transduction is almost
certainly an oversimplification, with issues such as the
importance of receptor phosphorylation and the events
dictating receptor transformation still unclear.108−111 Similarly,
while we have learned a great deal about the bHLH domain,
much is still to be learned about the N-terminal half of the
AHR. While the bHLH tail is thought to harbor both DNA
recognition and nuclear localization sequences (NLS), this
region also appears to play additional roles in receptor
signaling. In one example of this idea, this same region harbors
a nuclear export sequence (NES), which influences receptor
subcellular localization, and also a motif for cellular chaperone
interaction, which can influence receptor concentration and
transformation.71,112−114 Finally, our understanding of how
this domain interacts with the genome is probably also
Figure 4. Classic AHR signaling pathway. Prior to ligand binding, AHR remains in cytosol bound to HSP90, P23, and ARA9. When a ligand binds,
a conformational change occurs, exposing the nuclear localization sequence (NLS) in AHR’s N-terminus. Presentation of NLS permits the
translocation of AHR to the nucleus and subsequent dimerization with ARNT. The AHR−ARNT heterodimer recognizes and binds to AHREs in
the genome and initiates transcription of select genes. This interaction can be inhibited by AHRR, CYP1 metabolism of ligands, and post-
translational modification of the receptor.12,34,36,46,47,57,72,80−88,90−92,95,96,290,293,296,301
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incomplete. This conclusion is supported by the identification
of noncanonical enhancer target sites that are in addition to
classical AHREs as defined above.115
Similarly, our understanding of the C-terminal halves of
these proteins and the transactivation events they mediate is
also limited, with the role of specific coactivators in distinct
cellular responses still to be determined and the importance of
this domain in receptor transformation still unclear. An
improved understanding of the multiple coactivator inter-
actions and insights into their combinatorial and dynamic
nature will be important if we are to explain the wide variety of
cell-, species-, and ligand-specific responses induced by AHR
agonists and antagonists.90,95,115,106,117 In this regard, many of
the species-, tissue-, and ligand-dependent effects of AHR
agonists may be due to unique consequences of specific
coactivator recruitment within a given cellular environment (in
addition to differences in ligand-binding affinity/specificity).
Moreover, ligand-dependent recruitment of specific coactiva-
tors could underlie the unique pharmacology of distinct
agonist classes.
Dioxin-Like Compound Concept. An early observation that
has greatly influenced our thinking is that while most AHR
agonists can achieve similar efficacy with respect to
upregulation of AHH activity (i.e., CYP1A1, CYP1A2, and/
or CYP1B1), only the most potent and metabolically
recalcitrant (i.e., long T1/2) ligands induce the “dioxin toxic
syndrome.” Weaker agonists, such as the PAHs and variety of
natural ligands, which are rapidly metabolized and have lower
potency, appear to upregulate the CYP 1s but do not induce
chloracne and so on. The model proposed to explain this
phenomena is that there is a “restricted pleiotropic response”,
in addition to the upregulation of genes such as CYP1A1,
which is induced by longer-lived, pharmacologically unique
agonists, and this response is required for the dioxin toxic
syndrome.18 In fact, certain end points like CYP1A1 induction
(i.e., adaptive metabolism) can occur in response to a broad
spectrum of ligands, whereas end points of the dioxin toxic
syndrome appear to require receptor activation by compounds
with “dioxin-like” pharmacological properties. As a heuristic,
chlorinated dioxins, dibenzofurans, and biphenyls with
halogens in lateral positions show the greatest potential to
induce the dioxin toxic syndrome and are therefore often
designated as “dioxin-like compounds” (DLCs) (Figure 5).20
The idea that DLCs elicit effects that are distinct from other
classes of receptor ligands (like the PAHs) has regulatory
implications. Agencies such as the World Health Organization
(WHO) that direct global health efforts and agencies like the
Environmental Protection Agency (EPA) that govern chemical
releases within the United States employ the principle that
compounds of environmental concern that are structurally and
pharmacologically related to TCDD and that elicit toxicity
through a common mechanism are formally designated as
DLCs, and their exposures and release are regulated
concordantly.20 The principle used is that these compounds
are assessed for their relative effect potencies (REP) from
dose−response assessments for a pathological end point
associated with AHR activation and toxicity. This information
is used to generate toxic equivalency factors (TEFs), which are
weighted measures that reflect the relative potencies of a
pollutant of concern as compared to TCDD (Figure
5).23,118−123 Currently, TEFs are applied to 29 compounds
of environmental concern, 7 polychlorinated dibenzo-p-
dioxins, 10 polychlorinated dibenzofurans, and 12 polychlori-
nated biphenyls. The advantage of this approach is that it
provides a measure of toxicity from complex mixtures of
chlorinated dioxins, dibenzofurans, and biphenyls, which are
common in human exposure scenarios.
Insights from Naturally Occurring Structural Diver-
sity in the Ah Receptor. Genetic Variation/Polymorphism.
Early evidence indicates that the AHR was functionally and
structurally variable both within and across species. Support for
this idea arose from the observation that murine Ahr
polymorphisms lead to differential induction of P450s across
strains.35,42 Further, examination of additional animal species,
including hamster, guinea pig, rat, dog, and human, revealed
significant differences in sensitivity and response to diox-
ins.22,124,125 This idea of receptor diversity gained further
support with the development of antibodies and photoaffinity
radioligands that revealed biochemical differences in AHR
both across and within model species.126−129 The molecular
cloning of the AHR cDNAs from multiple animal species
revealed important codon polymorphisms in the Ahr gene that,
when paired with radioligand-binding experiments and
immunochemistry, led to the identification of codons that
influence receptor size and ligand-binding affinity (see
below).51,52,130,131
Molecular Insights from the Structural Gene. The AHR
structural gene, Ahr, resides on mouse chromosome 12 or on a
highly syntenic region on human chromosome 7.132−135
Comparison of the structural genes and cDNAs from mouse
and human indicates that the open reading frame is encoded
by 11 exons with highly conserved intron−exon boundaries
across species. A comparison of these genes reveals that
alternate termination codons for the open reading frame in
exon 11 explain much of the receptor size differences observed
within and across species. This molecular information indicates
Figure 5. Dioxin-like compound concept and approach to measuring
human exposure to mixtures. Toxic equivalency factors (TEFs) are
weighted measures that reflect the relative potencies of pollutants of
concern as compared to TCDD. Toxic equivalents (TEQs) are
reported values used for risk characterization and management (see
text for details). Left: Structures of the three classes of chlorinated
DLCs. Right: Examples of three formally designated DLCs. To
calculate TEQ, the mass of each chemical in a mixture is multiplied by
its TEF and summed.23,118,119121,123,208,302,303
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that the receptor open reading frame extends further in some
species (e.g., human and rat) and much less in others (e.g., the
C57BL/6J mouse). This leaves some proteins with longer C-
termini than others and explains how the AHR can be as small
as 97 kDa in the C57 mouse and as large as 105 kDa in the
human or 124 kDa in the hamster.127,129,131,134,136
Molecular Insights from the Mouse Model. The mouse is
an important animal model for the study of the AHR and its
signaling pathways. The initial mouse “responsiveness” poly-
morphism was explained through the comparison of the AHR
cDNAs derived from responsive (Ahrb allele) and the less
responsive strains (Ahrd allele). These experiments revealed
that there were numerous polymorphisms between the Ahrb
and Ahrd alleles.137−139 Among these is a polymorphism in the
stop codon, resulting in an additional 43 amino acids in the
carboxyl terminus of the AHRd receptor as compared to the
AHRb1 (identical to the cause of the cross-species differences
described above). Interestingly, two additional responsive
alleles were characterized (named Ahrb2 and Ahrb3),140 one
of which (Ahrb2) closely resembles the Ahrd allele in all but
three amino acids and includes an identical elongated c-
terminal tail. Using ligand binding of expressed polymorphic
proteins, it was concluded that a primary driver of the ligand-
binding affinity was residue 375, where an alanine (A) confers
higher affinity ligand binding and greater responsiveness in
mice harboring the b1, b2, and b3 alleles. In contrast, in Ahrd
mice, a valine (V) at this position confers lower affinity binding
and decreased responsiveness.138,139 Through investigations
into other residues, it was also observed that the elongated C-
terminal tail found in Ahrb2 and Ahrd mice may reduce ligand
binding slightly as compared to Ahrb1.139 It remains unclear the
extent the C-terminal half plays in ligand binding, as this region
also alters receptor stability and thus perhaps cellular
concentration.
Predictions of AHR structure have been modeled using
receptor homology data from other PAS family proteins, such
as HIF-2α. These analyses support the importance of residue
375 in ligand binding as well as the influence of alanine and
valine at this position.68,141−144 That is, the valine at 375
encoded by the Ahrd allele is bulkier and hypothesized to have
repulsive properties toward the ligand while also altering the
adjacent hydrogen bond network. Interestingly, the human
harbors a valine residue at this position, and this may be better
modeled by “humanized” or the AHRd models.145
Molecular Insights from the Rat Model. The rat has also
served as a powerful early model of AHR biology. This utility
arose from the classical use of this model as a tool in
toxicology, its sensitivity to TCDD induced carcinogenicity,146
and the existence of an informative polymorphism in the
receptor that influences a strain’s responsiveness to agonist.124
Similar to the mouse, some rat strains are resistant (Han−
Wistar, HW, 98 kDa), while others are sensitive (e.g., Long−
Evans, LE, or Sprague−Dawley, SD, 106 kDa) to the toxic and
inductive effects of ligands like TCDD. Through molecular
analysis of the cDNAs and structural genes of these AHR open
reading frames, it is now known that the explanation for
reduced signaling by the HW receptor is due to a variation at
the splice junction at exon−intron 10. While multiple
consequences of this altered splice junction can occur, this
polymorphism commonly leads to a truncation of the C-
terminal end of the HW-AHR, yielding as many as two novel
protein products possible.147 Physicochemical studies indicate
that this truncation reduces receptor concentration, possibly
due to influences on receptor stability or the potency of the
nearby transcriptionally active domains.147,148 This naturally
occurring receptor polymorphism in the rat provides
considerable evidence for the role of the receptor’s C-terminus
in AHR signaling and dioxin toxicity. An additional note is the
observation that while HW rats are resistant to many of the
acute toxic effects of high-dose dioxin exposure, they display
similar dose−response curve for end points such as CYP1A1
induction. Such a result would seem to be an indication that
classes of AHR-mediated biological/toxicological responses
exist, some of which require less receptor activation than
others.149,150 Such an observation is in keeping with the
restricted pleiotropic model described above.18
What Is the Normal Physiological Role of the Ah
Receptor? While the toxicology of PAHs and dioxins led to
the discovery of the AHR as well as the discovery of the AHR’s
roles in regulating xenobiotic metabolism, many significant
questions remain regarding the role of this receptor in normal
physiology. Perhaps one of the most important questions is
why this receptor exists in such a wide range of animal species
and in such a broad array of tissues and cell types? Early
research focused on the concept that the receptor was part of a
system that evolved to allow metabolic adaptation to
xenobiotics, especially PAHs, which have existed on the
earth for millennia due to natural processes such as fires and
volcanic activity.151 Parallel thinking suggests that the AHR
evolved as an allelopathic defense system, similar to those
systems reducing exposures to lipophilic natural products that
display toxicity when levels rise in an organism.152,153 While
these ideas are all probably correct in some form, it is also
probable that this is not the only physiological role of the AHR
nor are they the primary reason for its evolutionary
conservation (see below).
Lessons from Tissue and Cellular Expression. One
common approach used to deduce the physiological role of a
gene product is to determine where and when the protein is
expressed in an organism. This method relies on the premise
that tissue-specific or developmental expression will highlight
the relevant biological system. This approach has been used to
understand AHR biology and includes studies based upon
ligand binding, antibodies, and RNA analysis to report receptor
expression at the organ and tissue level.127,130,154−156 These
early studies are now complemented by high-throughput gene
expression resources such as BioGPS, ENCODE, and The
Human Protein Atlas.157−159
While the interpretation of the collective data from the
above sources is complex, a few important observations are
noteworthy. At the organ level, the AHR is expressed at many
sites, with the placenta expressing the highest levels of the
AHR mRNA in the human.130 The human lung is also a highly
expressing tissue in almost all reported studies and databases,
with levels in liver and bladder/urinary tract also reproducibly
high. In contrast to humans, in the mouse and rat, the lung is
typically the highest expressing organ and the placenta is much
lower. While issues such as gestation day may play a role in this
reported cross-species difference, it is notable that the human
placenta is physiologically distinct from rodent placentas.160
We draw two conclusions from these observations. The first is
that the AHR is most highly expressed at tissues that represent
important oxygen interfaces (lung and placenta). The second is
that if the AHR is important in human placental biology,
current animal models may significantly misrepresent this
important physiology.
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Predictions about endogenous function based on higher
resolution and temporal expression data (i.e., immunohisto-
chemistry and in situ hybridization techniques) are difficult to
simplify, because these studies describe AHR expression in a
remarkable array of cellular compartments and developmental
times. For example, in the E13.5 day embryo, the AHR is
highly expressed in the primitive pituitary, nasal septal
cartilage, dorsal surface of the tongue, developing thymus
lung parenchyma, liver, mucosa of the developing gut,
urogenital sinus, and genital tubercle.161 A parallel analysis of
the CNS indicates that AHR and ARNT are coexpressed in
regions of the hypothalamus and brainstem associated with
appetite and circadian regulation, and it is also highly expressed
in cardiac and skeletal muscle and epithelial regions associated
with epithelial to mesenchymal transitions.162−164 Adding to
this diversity, are reports of AHR expression in rabbit morula
and blastocysts, human pancreatic ductal and acinar cells,
immune cells of the intestinal stroma and ovarian granulosa
cells.165−168 Given that this is only a small list of unique sites of
AHR expression, it seems likely that this receptor will be
shown to have more than one significant role in normal animal
physiology and development.
Lessons from Ahr Null Rodents. Another method used to
identify putative physiological roles for the AHR is to create
mammalian models that are null for the Ahr gene product and
assess the consequences of that null allele on the host’s
biology. Generation of the null allele has been performed by at
least three independent laboratories for the mouse model and
at least once in the rat model.169,170,170,171,172 In rodent
models, the Ahr null allele has again provided evidence that the
AHR regulates multiple developmental and physiological
processes. In this regard, Ahr null mice have been reported
to display a number of phenotypes, including patent ductus
venosus, hepatic atrophy, altered immunity, vascular defects,
decreased barrier integrity of the skin and gut, and reduced
reproductive capacity.12,161,165,173−182 While initial reports of
variously generated mouse null alleles appear to display some
discordance, there is little evidence to indicate that any
differences are allelic; it is more likely they are due to genetic
background issues, unique pathogen loads, and different
dietary regimens.175
Interestingly, the rat null model displays a phenotype that is
distinct from the mouse, with pathological alterations primarily
in the urinary tract and kidney and no reported hepatovascular
pathology (i.e., patent ductus venosus) which is a hallmark
mouse phenotype studied in our laboratory.172 Moreover,
while immune effects in the mouse have predominantly been
studied for adaptive immunity and T-lymphocyte biology, the
effects in the rat have been reported primarily for B-
lymphocyte function.183−185 Taken in sum, these data strongly
support a role for the AHR in normal biology, with initial
indications of an important role for this receptor in barrier
integrity, immunity, reproduction, vascular development, as
well as hepatic and renal biology.165,183,186−188 Additionally,
these cross-laboratory and cross-species studies indicate that
experimental environment and genetic background are likely to
have a marked influence on AHR null phenotypes and AHR
biology writ large.
Lessons from Evolution. Another strategy to elucidate the
physiological role of the AHR is to study its evolution. Such an
approach anticipates that certain correlates might explain the
selective pressures that led to the receptor’s emergence and
maintenance in biological systems. The AHR, ARNT, and
AHRR are members of the bHLH-PAS family of transcription
factors, which arose early in evolution, with PAS domains
having been found in plants, animals, and bacteria.61,189
Domains reminiscent of PAS domains are found in
prokaryotes, where they play roles in phototropism and
oxygen sensing, and in plants, where they are involved in
photoreception and phototransduction.190
Diversification of the PAS gene family occurred early in
evolution. All of the major bHLH-PAS gene subfamilies (e.g.,
AHR, ARNT, HIF, SIM, CLOCK, TRH, BMAL, NCOA,
NPAS4) are shared by protostomes and deuterostomes and
thus must have been present already in the ancestral bilaterian
animal, which lived ∼570 million years ago.191,192 Metazoan
PAS domain-containing proteins play roles in a variety of signal
transduction pathways, many of which are involved in
developmental processes and environmental adaptation.193−195
Additional diversification of bHLH-PAS genes occurred early
in the vertebrate lineage as a result of two whole-genome
duplications,196 leading to the multiple paralogues (ohno-
logues) within each subfamily that exist in most vertebrates,
including mammals (e.g., three HIF genes, two CLOCK
genes).
The AHR genes have undergone duplication and diversifi-
cation like other bHLH-PAS genes, involving both whole-
genome duplications as well as a tandem duplication event.
The presence of multiple AHR genes in both bony and
cartilaginous fishes suggests that the AHR gene duplications
occurred early in vertebrate evolution, well before the
emergence of mammals.197,198 A tandem duplication produced
the genes now known as AHR1 and AHR2, which occur in
fish, birds, reptiles, and some early diverging mammals but
have been lost from most later mammalian groups. Another
duplication event produced AHRR, which evolved as a
transcriptional repressor of AHR function.99,199 In mammals,
AHRR may exhibit additional regulatory interactions besides
repressing AHR activity, consistent with data demonstrating
that human AHRR can have multiple effects on cell growth
and differentiation.199 Overall, phylogenetic and comparative
genomic analyses suggest that there are five groups (clades) in
the AHR subfamily: AHR, AHR1, AHR2, AHR3, and AHRR,
which exhibit gene- and taxon-specific functional special-
ization.198
Functional analyses of AHRs from extant vertebrate and
invertebrate species suggest that the ability to bind to planar
aromatic compounds such as PAHs and dioxins evolved in
early vertebrates. It has been hypothesized that one selective
force may have been the need to detoxify halogenated aromatic
natural products, which are prominent in the marine
environment, where early vertebrates arose.200,201 Although
AHR homologues from invertebrate species appear to lack the
ability to bind PAHs and dioxins, it is unknown if they can be
activated by other types of ligands.
While evolutionary information does not point us toward a
clear physiological role for the AHR, some intriguing
observations stand out from this analytical approach. First,
PAS domains have a propensity to exist in sensor proteins of
environmental stimuli such as light and oxygen ten-
sion.60,190,202 This role seems to have evolved early
(prokaryotes and plants) and been maintained throughout
millions of years of evolution. The AHR’s role as a chemical
sensor is consistent with this idea. Second, the AHR, as defined
by phylogenetic analysis (orthology) within the bHLH-PAS
family, has been found in almost all eumetazoan groups.198
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This suggests that whatever evolutionary pressures have led to
the maintenance of this gene, they have existed for millennia.
Third, there may be a common thread that unites AHR
function across the metazoan: such as a role in controlling cell
fate during the development of neural systems and, in
particular, sensory structures. For example, in the cnidarian
Nematostella, AHR is expressed in the apical tuft (a sensory
structure).192 In arthropods (e.g., Drosophila), AHR controls
the development of the distal segment of the antenna (a
chemosensory structure), mechanosensory bristles, and photo-
receptors.203,204 In nematodes (e.g., C. elegans), AHR controls
the development of touch receptor neurons and sensory
neurons that contact the pseudocoelomic fluid.205 Emerging
evidence for a role of AHR in neural development in mammals
suggests this could be one possible conserved role shared by all
animals.198,206 Despite these intriguing findings, it will remain a
challenge to identify conserved physiological roles of AHRs
and to distinguish them from novel functions that evolved in
specific taxonomic groups.
Diversity of AHR Ligands. Structure−Activity Relation-
ships. Early structure−activity relationship (SAR) analysis
based on various halogenated aromatic hydrocarbons (HAHs),
PAHs, and related compounds, suggested that the AHR ligand-
binding pocket binds near-planar ligands with dimensions that
approximated a 3 × 10 Å (Å) rectangle.18,207 More recent
analyses based, in part, on structure−activity studies and on
structural similarity to crystallized domains of other PAS
proteins, support the idea that absolute planarity is not a
requirement for receptor binding and that maximal dimensions
of the ligand-binding pocket may be more closely approxi-
mated by a pocket of 14 × 12 × 5 Å (reviewed in ref 153). It
has also been observed that both the hydrophobicity and the
polarizability of a compound’s substituents add an additional
layer of complexity in regards to affinity for AHR.153,208−212
While current structural models are useful, a solved binding
pocket structure through X-ray crystallography or NMR is
needed if we are to confidently predict chemical binding to the
AHR and anticipate the biological effects that emerging
environmental pollutants and therapeutics will induce. In the
meantime, those of us with limited expertise in physical
chemistry are left with a preliminary “flat hydrophobic
rectangle” (FHR) model as a predictor of AHR ligand-binding
activity (Figure 6).
Several reviews have provided a comprehensive description
of the structural diversity of AHR ligands and sour-
ces.24,153,208,213 While structural classification of AHR ligands
based upon chemical backbone is useful (dioxins, biphenyls,
PAHs, flavonoids, etc.), it is also useful to think of these
compounds based upon nonstructural properties, such as
source, risk for human exposure, receptor binding affinity, and
biological half-life. In this regard, ligands coming from
anthropogenic sources such as diesel exhaust, commercial
production, or industrial contamination (PAHs, PCBs, and
dioxins), are produced as natural products, or they are
generated endogenously in human tissues (indigoids, indolo-
carbazoles, etc.). For many of these source classes, member
ligands display EC50 values or binding affinities for the AHR
that differ by multiple orders of magnitude. Ligands from these
source classes can also harbor markedly different biological
half-lives that span from hours to months.214−216
Importance of Proligands. An important concept to
consider is that many compounds that are thought to activate
the AHR are not actual ligands of the AHR but are proligands.
Proligands are precursors that are chemically transformed to
the ultimate ligand, which strongly binds to the AHR pocket.
Proligands typically form the ultimate ligands via condensation
reactions of precursor molecules into larger planar, more
stable, polycyclic aromatics.217,218 Such reactions can often be
spontaneous or nonenzymatic. The first discovered and
perhaps clearest example of a proligand is indole 3-carbinol
(I3C) produced in broccoli, Brussels sprouts, and kale. This
naturally occurring 3-substituted indole is produced from
enzymatic breakdown in the plant tissue from a glucosinolate
known as glucobrassicin.218−220 Indole-3-carbinol was origi-
nally studied as an anticarcinogenic substance by virtue of its
activity as an inducer of carcinogen metabolism.221,222 The
premise was that dietary I3C protected against coadministered
carcinogens such as BAP and DMBA by “blocking” their action
through a reduction in their relative metabolic flux to ultimate
electrophiles that damage DNA.223 Interestingly, we now know
that I3C itself is not a ligand of the AHR, but when I3C is
ingested, it hits the low pH environment of the stomach and
spontaneously undergoes an acid-catalyzed condensation
Figure 6. The flat hydrophobic rectangle model of AHR ligands. Molecular and ball and stick models of some AHR ligands discussed in this review
that conform to the FHR concept of ligand structure. The three-dimensional structures are only provided as approximations, as some subtle
bending and puckering of structure may occur that is not predicted by common algorithms. Figure was generated with ChemDraw software.
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reaction, converting it to a variety of AHR ligands including
the potent agonist indolo[3,2-b]carbazole (ICZ).218,224,225
Condensation products of I3C, such as ICZ, are high-affinity
binders of the AHR and can be found in the bloodstream after
exposure to I3C in the diet.218
One important lesson to be learned from the proligand idea
is that when a compound does not fit the FHR model
described above, some caution should be ascribed to any
inclusion of the compound into a list of bona f ide endobiotic or
xenobiotic ligands. A list of “nonclassical” compounds that
activate CYP1A1 expression but that do not obviously fit the
FHR model is included in a recent review and includes
SKF71739, thiabendazole, omeprazole, and 1,5-diaminonap-
thalene.153 We propose that, often, such ligands may actually
be proligands. In addition to I3C described above, a number of
other examples support the concept that proligands are a
common source of receptor activation, including the
identification of alanine serine aminotransferase (AST) and
D-amino acid oxidase (DAO) as enzymes capable of activating
the AHR in cell culture.226,227 The biochemical explanation for
receptor activation by these enzymes is the generation of
indole-3-pyruvic acid (I3P) from tryptophan (TRP) through
deamination.226,228 Like I3C, I3P is a reactive indole, and this
α-keto acid spontaneously condenses to a number of di-indol
structures and possibly related backbones that are the ultimate
AHR ligands or a more proximal precursor to them.228
Similarly, in recent studies of the immune system, numerous
laboratories made the observation that small relatively polar
immunomodulators produced from TRP by the enzyme
indoleamine 2,3-dioxygenase (IDO) can activate the AHR.229
Given the lack of fit of many of these IDO products to the
FHR model, it was again shown that IDO products such as
kynurenine (KYN) or 3-hydroxyanthranilic acid (3HAA) are
also proligands that are converted to a series of “trace extended
aromatic condensation products” (TEACOPs).230,231 It is
probable that molecules such as these are high-affinity ligands
and potent AHR agonists in vivo.
The idea that proligands may be more common than is
currently appreciated may explain how AHR ligands display so
much reported structural diversity. In our simplistic view, it
may be that all AHR ligands must fit the FHR model, and
when a structure does not fit, it is more likely a proligand
rather than a true ligand. Either it is being converted to a
TEACOP or the TEACOP is a trace contaminant of the
material being used in the experiment. In this regard, if one
examines a potential ligand with a high EC50 for induction of
an AHRE-mediated response, some consideration of the
possibility that the ligand is contaminated with, or is generating
TEACOPs, should be considered. In this regard, I3C has an
EC50 that is approximately 5 orders of magnitude higher than
ICZ for competition with TCDD for AHR occupancy (i.e., 5
orders of magnitude lower affinity).218 In the absence of acid
condensation conditions, the I3C response may be explained
by the contamination of ICZ equivalents at 1 part in 100 000
(0.001%). We argue that many compounds that are activators
of the AHR at high concentrations may be contaminated with
or generate a series of TEACOPs, thereby confusing
structure−activity relationships.
Classifying Ligands: Xenobiotic, Endobiotic, and Cog-
nate. We often think of AHR ligands as existing in two
physiologic classes: “xenobiotic” and “endobiotic.” We employ
the term xenobiotic for those compounds found in an
organism that are not produced within that organism. Their
presence in the organism is “foreign” or from a foreign source
(“xeno”).232 Common sources of xenobiotic ligands include
diesel exhaust (e.g., PAHs), chlorophenol manufacturing (e.g.,
dioxins), or pharmaceutics (e.g., omeprazole). Xenobiotic
ligands can also be “natural” and include normal constituents
of fruits and vegetables (e.g., chrysin, quercetin, and
galanin).233−235 In contrast, we reserve the term endobiotic
ligand to denote any AHR ligand that is produced readily in a
given biological system, including within the gastrointestinal
tract. A few widely studied endogenous ligands are 6-
formylindolo[3,2-b]carbazoles (FICZ), 2-(1′H-indole-3-car-
bonyl)-thiazole-carboxylic acid methyl ester (ITE), indigo,
indirubin, and bilirubin.236−239
A final definition that may also be useful going forward is the
term “cognate.” We use this term to refer to those ligands that
have provided the selective pressure for the evolutionary
conservation of the AHR. This class of ligand has also been
referred to as “the endogenous ligand”, “the physiological
ligand”, or even “the ancient ligand.” We define cognate ligands
as those ligands that correspond to the evolutionary pressure
that has led to the emergence and maintenance of this receptor
through evolution. Put another way, these are the ligands that
have the most important consequences on normal physiology.
In the absence of these ligands, the organism cannot thrive
under all developmental and physiological stresses. This
concept of the cognate ligand is important, because it implies
that the AHR has evolved in parallel with a ligand (or set of
ligands) as its evolutionary pressure. In turn, this implies that
the AHR has a physiological role that is separate from and in
addition to the adaptive metabolism of xenobiotics.
Xenokine Model of Ah Receptor Signaling. In a
previous review, rudimentary models of AHR signaling have
been put forth that might explain how potent DLCs lead to the
dioxin toxic syndrome.18,36 Given that many of those models
are still untested or unrefuted, we have turned our attention
toward an understanding of the AHR’s cognate signaling with
the underlying idea that such insight will explain many of the
pathological consequences of DLCs. Based upon this history,
the ideas presented above, and the models of toxicity described
previously, we close this manuscript with an attempt to provide
testable models of AHR cognate signaling. While our initial
plan was to summarize all the ideas that have been put forth in
the peer-reviewed literature, we found that there were so many
ideas and so much intriguing evidence, that we could not
objectively integrate them all. In this regard, the remarkable
breadth of phenotypes influenced by AHR biology is provided
in a recent review and reflects a potential role for this receptor
in almost every major organ system and an influence on
processes as diverse as cell cycle progression, immunity, DNA
biochemistry, reproduction, and circadian rhythmicity.12
Therefore, we chose to articulate a parsimonious model that
employs ideas borrowed from the works of many AHR
scientists but that is interpreted through the prism of our own
laboratory ’s research experience over the last 30
years.12,18,169,186,240−245
This integrated model of cognate signaling has its roots in
the adaptive metabolism of PAHs, dioxin toxicology, and
recent results from AHR null mouse models.12,18,169,186,241−245
We refer to this way of thinking about AHR biology as the
“xenokine model.” The xenokine model is based on the idea
that there is parallelism between AHR’s role in the adaptive
metabolism of xenobiotic environmental ligands and a similar
class of endobiotic ligands that we collectively think of as
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“xenokines.” These xenokines are generated within the
organism but commonly outside of cells, such as in interstitial
spaces, the lumens of organs, or regions of cellular disruption.
We propose that these xenokines are generated by endogenous
chemical reactions that generate agonists in a manner similar
to the generation of agonists found in the environment. In
turn, these xenokines are sensed by the AHR, which stimulates
a transcriptional response that is linked to a new physiological
state better adapted to the new challenge they represent. Like
the adaptive response to xenobiotics, it follows that the
pathway is under feedback regulation and xenokine action is
rapidly attenuated through CYP1 induction, AHRR upregula-
tion, and so on.
We predict that xenokines may be as structurally varied as
the spectrum of known environmental ligands but will fit the
FHR model described above. We anticipate that the
identification of all cognate ligands may be difficult to achieve
due to the possibility that each tissue or organ system may
have its own unique variety of xenokines that arise from the
distinctive chemistries of each specific tissue and environ-
mental stimuli. While the exact identity of the cognate ligands
are still to be elucidated, evidence from the literature suggests
they could arise from products of polyunsaturated fatty acids
or heme metabolites, or they could be produced from aromatic
amino acids like TRP through enzymatic reactions, non-
enzymatic condensation reactions, free radical reactions,
microbial metabolism, inflammation, and UV irradia-
tion.12,153,208,246−251
Aromatic amino acids such as TRP and phenylalanine are
potentially important proligands and sources of AHR cognate
ligands.226,252−254 In fact, the molecule that has the most
experimental support for this definition of xenokine is the TRP
photoproduct and TEACOP known as FICZ.246 Evidence that
this indolocarbazole is an important cognate ligand includes
the observations that FICZ harbors an AHR binding affinity
among the highest ever observed, is produced endogenously at
epithelial barriers in response to UV irradiation, and appears to
play a role in AHR-mediated immune and epithelial response
to environmental stressors including bacterial invasion, oxygen
stress, and UV damage.186,246 Moreover, FICZ is rapidly
metabolized by the CYP1 monooxygenases, implying its levels
are tightly regulated by the feedback loop described above.214
Lesser but provocative evidence exists for the physiological
importance of additional TRP-related xenokines at other
tissues. For the intestinal barrier, evidence supports the idea
that TRP metabolites arising from gut microflora play
important roles in activating AHR signaling to influence gut
barrier integrity through influence on intestinal lymphocyte
populations (e.g. refs 255−257). Even more speculative is the
idea that products of the enzyme DAO, which harbors
metabolic activity toward D-amino acids such as D-TRP found
in bacteria, or AST, which harbors metabolic activity toward
TRP, can both generate the AHR proligand I3P.226−277,228,252
Thus, oxidases, deaminases, and transaminases like these have
potential to generate proligands and ultimately xenokines in
vivo. Enzymatic mechanisms such as these also have the
potential to generate xenokines not only at environmental
interfaces but also internally under conditions of tissue
damage, inflammation, or remodeling.
In its simplest form, the above model can be summarized as
follows. Tissues experience alterations in their external
environment or their neighboring cellular environment,
through inflammation, tissue damage, UV exposure, devel-
opmental remodeling, and changes in microbial populations or
oxygen concentration. Each of these changes yields a unique
chemistry that produces xenokines through reactive proligand
intermediates that activate an AHR-mediated physiological
response at the tissue level. In the gut and skin, the response is
exemplified by increased barrier integrity, possibly through an
influence on resident lymphocyte populations. In the lungs,
hyperoxia may be eliciting its own unique chemistry and
subsequent xenokine production to adapt to a new higher
oxygen tension or microbiological challenges presented by the
ambient air at parturition.248,258 In the vascular system, tone
and vascular remodeling may respond to systemic release of
xenokines or through internal production consequent to
cellular remodeling, changes in oxygen tension, or shear
stress.259,260
Outputs of Xenokine Signaling. This perspective has
emphasized the AHR signaling pathway as an adaptive
metabolic system with the plan to dedicate a future perspective
on the identities of those target or output genes that might
facilitate the physiological and toxicological consequences of
receptor activation. While evidence for the significance of this
pathway in adaptive metabolic ligand clearance is recounted
above, two pieces of evidence show how tightly this adaptive
response must be regulated in vivo. In one example,
competitive inhibition of CYP1 activity by ligands was
shown to influence the signaling of the putative cognate ligand
FICZ, presumably by reducing its clearance and increasing its
steady state.214 In another example, the global/constitutive
expression of the Cyp1a1 gene in the mouse induced a partial
phenocopy of the AHR null phenotype, presumably by
reducing levels of an essential cognate ligand and/or
CYP1A1 substrate.261
It is also important to note here that there is evidence both
for and against the centrality of CYP 1s as outputs essential for
the physiological or toxicological effects of this receptor.
Arguing for their importance as outputs is evidence that such
monooxygenases influence the levels of lipid mediators (LMs)
derived from polyunsaturated fatty acids or arachidonic
acid.12,249 Such LMs could have broad vaso- and immune
activities that may ultimately explain aspects of DLC
toxicology or phenotypes observed in AHR null models. A
separate idea is that some of DLC toxicity or cognate
physiology may be mediated through AHR’s role as a sensor
of reactive oxygen species or even mediator of an oxidative
stress response.262−265 While many related ideas have been
proposed, one of the longest-standing is that the upregulation
of CYP1-dependent monooxygenases leads to an increase in
reactive oxygen species, which in turn can influence cellular
physiology.266−268 Arguing against the importance of CYP 1s
as important output genes are observations from our own
laboratory, in which the CYP1A1/CYP1A2 upregulation can
be genetically dissociated from hallmark phenotypes of the
AHR null model (e.g., patent ductus venosus) or classical toxic
end points from TCDD exposure.269,270
Finally, the AHR field has been heavily focused on the idea
that a cognate ligand exists. While we have argued for the
importance of xenokine ligands as well as the adaptive response
for xenobiotic and xenokine ligands, the AHR may also
function constitutively in some situations. Such a possibility is
supported by the expansive evolutionary data described above,
where AHR orthologues exist that do not appear to recognize
any ligand and appear to signal constitutively and the
observation that ligand recognition of PAHs seems to be a
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vertebrate receptor characteristic. Despite all the data on the
hundreds of xenobiotic ligands and the preliminary data related
to cognate ligands like FICZ, we must be accepting of the
formal possibility that the AHR is a bifunctional transcription
factor, a transcription factor with both intrinsic activity and
ligand-inducible transactivating properties.
In Closing. The AHR field is abundant with evidence for its
role in biological processes as disparate as immunity, vascular
biology, stemness, neurosensory signaling, reproduction, cell
cycle regulation, and nucleic acid biochemistry. We began this
perspective with the objective of developing a comprehensive
review of modern thought related to the role of the AHR in
normal human physiology. The review evolved into a
discussion of the adaptive metabolism paradigm and the
promotion of the xenokine model. We conclude recognizing
that we have only touched the surface, only having discussed a
small portion of the provocative ideas that have been put forth
over the past 50 years. As we move forward into the next half-
century of AHR research we must continue asking: How can
all these AHR-mediated biological processes be true? How can
dioxins cause so many distinctive effects? As this effort unfolds,
we suspect that the simpler answer will be the correct one and
look forward to the development of an understanding of AHR
signal transduction that unifies the many scientific disciplines
that have been touched by this enigmatic signaling molecule.
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